Short-Term, High-Dose Fish Oil Supplementation Increases the Production of Omega-3 Fatty Acid-Derived Mediators in Patients With Peripheral Artery Disease (the OMEGA-PAD I Trial)
Grenon SM, Owens CD, Nosova EV, Hughes-Fulford M, Alley HF, Chong K, Perez S, Yen PK, Boscardin J, Hellmann J, Spite M, Conte MS
Journal of the American Heart Association · 72 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institute on Aging
- Gobierno
- National Heart, Lung, and Blood Institute
- Gobierno
- National Center for Research Resources
- Gobierno
- National Center for Advancing Translational Sciences
- Gobierno
- NHLBI NIH HHS
- Gobierno
- NCATS NIH HHS
- Gobierno
- NIA NIH HHS
- Gobierno
- NCRR NIH HHS
- Subvenciones
- National Center for Advancing Translational Sciences (KL2-TR-000143); National Heart, Lung, and Blood Institute (HL-106173); National Center for Research Resources (KL2RR024130); National Heart, Lung, and Blood Institute (HL-116186); National Heart, Lung, and Blood Institute (R01HL119508); National Heart, Lung, and Blood Institute (F32 HL116186); National Heart, Lung, and Blood Institute (K23 HL122446); National Heart, Lung, and Blood Institute (1K23HL122446-01); National Institute on Aging (UH3-AG037628); National Heart, Lung, and Blood Institute (R01HL106173)
Según 8 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2015-08-25 · J Am Heart Assoc · vol. 4 · número 8 · pág. e002034
- Editorial
- Wiley
- Citado
- 84 citas · más que el 96% de estudios similares · 5.9× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 80 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY-NC
- Áreas de investigación
- Fatty Acid Research and Health · Peripheral Artery Disease Management · Cardiovascular Health and Disease Prevention
- Palabras clave
- fish oil supplementation, omega-3 polyunsaturated fatty acids, peripheral arterial disease, endothelial function, flow-mediated dilation, specialized pro-resolving mediators, omega-3 index, triglycerides, inflammation, claudication, lipid profile
- MeSH
- brachial artery, humans, fatty acids, omega-3, triglycerides, fish oils, inflammation mediators, treatment outcome, administration, oral, double-blind method, vasodilation, exercise tolerance, time factors, dietary supplements, aged, middle aged, san francisco, female, male, peripheral arterial disease, biomarkers, surveys and questionnaires
12 autores
- S. Marlene Grenon🇺🇸 · autor de correspondenciaSan Francisco VA Medical Center; University of California, San Francisco
- Christopher D. Owens🇺🇸San Francisco VA Medical Center; University of California, San Francisco
- Emily V. Nosova🇺🇸University of California, San Francisco
- Millie Hughes‐Fulford🇺🇸San Francisco VA Medical Center; University of California, San Francisco
- Hugh F. Alley🇺🇸University of California, San Francisco
- Karen C Chong🇺🇸University of California, San Francisco
- Sandra Perez🇺🇸San Francisco VA Medical Center
- Priscilla K. Yen🇺🇸University of California, Los Angeles
- W. John Boscardin🇺🇸University of California, San Francisco
- Jason L. Hellmann🇺🇸Brigham and Women's Hospital; Harvard University
- Matthew R. Spite🇺🇸Brigham and Women's Hospital; Harvard University
- Michael S. Conte🇺🇸University of California, San Francisco
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Patients with peripheral artery disease (PAD) experience significant morbidity and mortality. The OMEGA-PAD I Trial, a randomized, double-blinded, placebo-controlled trial, addressed the hypothesis that short-duration, high-dose n-3 polyunsaturated fatty acids (n-3 PUFA) oral supplementation improves endothelial function and inflammation in PAD.
Methods and results
Eighty patients with stable claudication received 4.4 g of fish oil or placebo for 1 month. The primary end point was endothelial function as measured by brachial artery flow-mediated vasodilation. Secondary end points included biomarkers of inflammation, n-3 polyunsaturated fatty acids metabolome changes, lipid profile, and walking impairment questionnaires. Although there was a significant increase in FMD in the fish oil group following treatment (0.7±1.8% increase from baseline, P=0.04), this response was not different then the placebo group (0.6±2.5% increase from baseline, P=0.18; between-group P=0.86) leading to a negative finding for the primary endpoint. There was, however, a significant reduction in triglycerides (fish oil: -34±46 mg/dL, P<0.001; placebo -10±43 mg/dL, P=0.20; between-group differential P-value: 0.02), and an increase in the omega-3 index of 4±1% (P<0.001) in the fish oil group (placebo 0.1±0.9%, P=0.49; between-group P<0.0001). We observed a significant increase in the production of pathway markers of specialized pro-resolving mediators generated from n-3 polyunsaturated fatty acids in the fish oil group.
Conclusions
High-dose, short-duration fish oil supplementation did not lead to a different response in the primary end point of endothelial function between the treatment and placebo group, but improved serum triglycerides and increased the production of downstream n-3 polyunsaturated fatty acids-derived products and mediators in patients with PAD.
Clinical trial registration
URL: https://www.clinicaltrials.gov/. Unique identifier: NCT01310270.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.